Regeneron Pharmaceuticals, Inc.

-2.16 (-0.39%)

Regeneron Pharmaceuticals Says FDA Accepts Dupixent (Dupilumab) For Review In Children With Moderate-To-Severe Asthma

Published: 03/04/2021 06:14 GMT
Regeneron Pharmaceuticals, Inc. (REGN) - FDA Accepts Dupixent® (dupilumab) for Review in Children With Moderate-to-severe Asthma.
Regeneron Pharmaceuticals- Target Action Date for FDA Decision is October 21, 2021.
Regeneron Pharmaceuticals- Eu Regulatory Submission for Children Aged 6 to 11 Years With Asthma is Planned for Q1 2021.